Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.62 |
| ▸ | DRD3 | P35462 | 4/20 | 0.62 |
| ▸ | DRD4 | P21917 | 1/20 | 0.62 |
| ▸ | HTR1D | P28221 | 2/20 | 0.61 |
| ▸ | HTR1A | P08908 | 6/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 5/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316599 | 1.00 | DRD2 (0.62) | DRD2DRD3DRD4HTR1DHTR1A | |
| SCHEMBL3316605 | 1.00 | DRD2 (0.62) | DRD2DRD3DRD4HTR1DHTR1A | |
| SCHEMBL3315780 | 0.90 | DRD2 (0.58) | DRD2DRD3DRD4HTR1DHTR1A | |
| SCHEMBL3315773 | 0.90 | DRD2 (0.58) | DRD2DRD3DRD4HTR1DHTR1A | |
| SCHEMBL338383 | 0.86 | DRD2 (0.57) | DRD2DRD3DRD4HTR1D | |
| SCHEMBL338382 | 0.86 | DRD2 (0.57) | DRD2DRD3DRD4HTR1D | |
| SCHEMBL338959 | 0.79 | DRD2 (0.52) | DRD2DRD3DRD4HTR1D | |
| SCHEMBL338960 | 0.79 | DRD2 (0.52) | DRD2DRD3DRD4HTR1D | |
| SCHEMBL10043014 | 0.78 | DRD2 (0.51) | DRD2DRD3DRD4HTR1D | |
| SCHEMBL10043006 | 0.78 | DRD2 (0.51) | DRD2DRD3DRD4HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348358-A1 | Serotonin Receptor Modulators | UNITED STATES GOVERNMENT | 2023-11-02 | — | — | US | disclosed |
| US-20230348358-A1 | Serotonin Receptor Modulators | UNITED STATES GOVERNMENT | 2023-11-02 | — | — | US | disclosed |
| US-8236845-B2 | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-08-07 | — | — | US | disclosed |
| US-20100105684-A1 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | disclosed |
| EP-2142511-A2 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008116663-A2 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105684-A1 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | HNMT, NNT, NQO1 | DRD2 1527/4885DRD3 1739/4885DRD4 1603/4885 |
| US-20230348358-A1 | Serotonin Receptor Modulators | HTR7, HTR1A, HTR5A | DRD2 298/4885DRD3 834/4885DRD4 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.